Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols

Historically, t(1;19)(q23;p13.3) has been related to pre-B acute lymphoblastic leukemia (ALL) and associated with a poor prognosis. Current treatments have overcome this dismal outcome, but advantages in survival for the unbalanced group have been reported. We compared the outcome of balanced and un...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2011-07, Vol.52 (7), p.1215-1221
Main Authors: Felice, MarÍa S., Gallego, Marta S., Alonso, Cristina N., Alfaro, Elizabeth M., Guitter, Myriam R., Bernasconi, Andrea R., Rubio, Patricia L., Zubizarreta, Pedro A., Rossi, Jorge G.
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Asparaginase - therapeutic use
Basic Helix-Loop-Helix Transcription Factors - genetics
Child
Child, Preschool
childhood
Cytogenetic Analysis
Daunorubicin - therapeutic use
Disease-Free Survival
DNA-Binding Proteins - genetics
E2A-PBX1 fusion transcript
Humans
Immunophenotyping
Infant
Pre-B-Cell Leukemia Transcription Factor 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Prednisone - therapeutic use
Prognosis
prognostic value
Proto-Oncogene Proteins - genetics
t(1
19)
Translocation, Genetic - genetics
Treatment Outcome
Vincristine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Historically, t(1;19)(q23;p13.3) has been related to pre-B acute lymphoblastic leukemia (ALL) and associated with a poor prognosis. Current treatments have overcome this dismal outcome, but advantages in survival for the unbalanced group have been reported. We compared the outcome of balanced and unbalanced der(19)t(1;19) cases and also patients with t(1;19)/TCF3-PBX1 versus patients without this translocation, to assess its prognostic value. From January 1990 to December 2010, t(1;19)(q23;p13)/TCF3-PBX1 was detected in 48 cases. Patients were treated with Berlin-Frankfurt-Münster (BFM)-based protocols and classified into balanced (n = 17) and unbalanced (n = 23) groups. The probability of event-free survival (pEFS) (standard error) of patients with t(1;19)/TCF3-PBX1 was 85% (6%), for the unbalanced group 78% (10%), and 88% (8%) for the balanced. The pEFS of patients with t(1;19)/TCF3-PBX1 was significantly superior to that of patients without t(1;19)/TCF3-PBX1 (p-value
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2011.565436